Company intelligence / Profile preview

ChemT Biotechnology

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

The company has developed an AI-powered platform to enhance the efficacy and accessibility of T cell therapies such as CAR-T. Their lead product, CMT‑01, reportedly delivers a 5–10x improvement in T cell production for these therapies. No clinical results are available yet.

Therapeutic areas: Oncology
Modalities: T cell therapies (specifically CAR-T)biologicsAI-driven cell therapy production
Industry: Non-Drug Biotech

Drug pipeline

1 asset

Chemplify

Commercial

Indications: T cell therapy manufacturing

Beyond the preview

Go deeper on ChemT Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChemT Biotechnology.

Explore the full profile